Unicycive Therapeutics, Inc.
NASDAQ:UNCYBiotechnology
-$0.24 today
- Market cap
- $104.19M
- Beta
- 1.73
- P/E (TTM)
- -40.8
- EPS (TTM)
- -$0.17
Volume 1.39M
Average 0.65M
UNCY Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Unicycive Therapeutics, Inc.NASDAQ: UNCY
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 89.0% from a year ago
Cash & equivalents stood at $37.37M at the end of Q1 FY2026, up 89.0% from a year earlier and up 28.0% from the prior quarter. Over 3 fiscal years it compounded at +300.4% a year.
Context
- Cash & equivalents amounted to 58.0% of total assets at the end of Q1 FY2026, down 12.7 pp from a year earlier.
- Cash & equivalents increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +89.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 29.2M USD
- Year-over-year change
- +11.7%
- 4-year CAGR
- +15.2%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 29.2M | +11.7% |
| FY2024 | 2024-12-31 | 26.14M | +169.5% |
| FY2023 | 2023-12-31 | 9.7M | +2032.1% |
| FY2022 | 2022-12-31 | 455K | -97.3% |
| FY2021 | 2021-12-31 | 16.58M | — |
Cash & Equivalents vs competitors
How UNCY compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +89.0% is the 4th highest of 10, against a peer median of +28.6%.
- Cash & equivalents amounts to 58.0% of total assets for UNCY, versus a peer median of 40.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $186.63M USD | +1204.7% | -47.5% | 98.4% | |
| Mar 2026 | $99.21M USD | +101.1% | — | 94.1% | |
| Mar 2026 | $50.75M USD | +76.8% | +6.9% | 28.2% | |
| Mar 2026 | $44.69M USD | +24.6% | -20.7% | 96.4% | |
| Mar 2026 | $39.13M USD | -23.8% | -29.5% | 40.5% | |
| Mar 2026 | $37.37M USD | +89.0% | +300.4% | 58.0% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | Mar 2026 | $34.06M USD | -13.0% | +12.0% | 31.6% |
CBUSCibus, Inc. | Mar 2026 | $30.33M USD | +28.6% | +42.5% | 9.4% |
HYFTMindWalk Holdings Corp. | Jan 2026 | CA$14.18M CAD | +9.8% | -29.1% | 61.2% |
| Mar 2026 | $9.78M USD | +750.3% | -13.5% | 4.2% | |
| Peer median (excluding UNCY) | — | +28.6% | -17.1% | 40.5% | |
Competitors are the stored peer set for UNCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Unicycive Therapeutics, Inc.
NASDAQ:UNCY
Intrinsic Alpha fair value
Locked
Current Price
$3.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.